Jayakumar Sreenivasan1, Urvashi Hooda1, Pragya Ranjan1, Diwakar Jain2,3. 1. Westchester Medical Center, Heart and Vascular Institute, New York Medical College, Valhalla, NY, USA. 2. Westchester Medical Center, Heart and Vascular Institute, New York Medical College, Valhalla, NY, USA. dj2700@gmail.com. 3. Department of Cardiovascular Medicine, Westchester Medical Center, 100 Woods Road, Valhalla, NY, 10595, USA. dj2700@gmail.com.
Abstract
PURPOSE OF REVIEW: In this review, we summarize the major known cardiac toxicities of common chemotherapeutic agents and the role of nuclear cardiac imaging for the surveillance and assessment of cancer therapeutics-related cardiac dysfunction in routine clinical practice. RECENT FINDINGS: Cardiotoxicity from chemotherapy causes a significant mortality and limits potentially life-saving treatment in cancer patients. Close monitoring of cardiac function during chemotherapy is an accepted method for reducing these adverse effects especially in patients with cancer therapeutics-related cardiac dysfunction. Nuclear imaging is a sensitive, specific, and highly reproducible modality for assessment of cardiac function. Nuclear imaging techniques including equilibrium radio nucleotide angiography, myocardial perfusion imaging, and novel experimental molecular imaging are the various objective tools available in addition to conventional echocardiography and cardiac magnetic resonance imaging in the surveillance, assessment, and follow-up of cancer therapeutics-related cardiac dysfunction.
PURPOSE OF REVIEW: In this review, we summarize the major known cardiac toxicities of common chemotherapeutic agents and the role of nuclear cardiac imaging for the surveillance and assessment of cancer therapeutics-related cardiac dysfunction in routine clinical practice. RECENT FINDINGS:Cardiotoxicity from chemotherapy causes a significant mortality and limits potentially life-saving treatment in cancerpatients. Close monitoring of cardiac function during chemotherapy is an accepted method for reducing these adverse effects especially in patients with cancer therapeutics-related cardiac dysfunction. Nuclear imaging is a sensitive, specific, and highly reproducible modality for assessment of cardiac function. Nuclear imaging techniques including equilibrium radio nucleotide angiography, myocardial perfusion imaging, and novel experimental molecular imaging are the various objective tools available in addition to conventional echocardiography and cardiac magnetic resonance imaging in the surveillance, assessment, and follow-up of cancer therapeutics-related cardiac dysfunction.
Entities:
Keywords:
Cardiotoxicity; Chemotherapeutic agents; MUGA scan; Nuclear imaging
Authors: Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-06-11 Impact factor: 508.702
Authors: Valentina Guarneri; Daniel J Lenihan; Vicente Valero; Jean-Bernard Durand; Kristine Broglio; Kenneth R Hess; Laura Boehnke Michaud; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Francisco J Esteva Journal: J Clin Oncol Date: 2006-08-14 Impact factor: 44.544
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: M A de Korte; E G E de Vries; M N Lub-de Hooge; P L Jager; J A Gietema; W T A van der Graaf; W J Sluiter; D J van Veldhuisen; T M Suter; D T Sleijfer; P J Perik Journal: Eur J Cancer Date: 2007-08-24 Impact factor: 9.162
Authors: G Curigliano; D Lenihan; M Fradley; S Ganatra; A Barac; A Blaes; J Herrmann; C Porter; A R Lyon; P Lancellotti; A Patel; J DeCara; J Mitchell; E Harrison; J Moslehi; R Witteles; M G Calabro; R Orecchia; E de Azambuja; J L Zamorano; R Krone; Z Iakobishvili; J Carver; S Armenian; B Ky; D Cardinale; C M Cipolla; S Dent; K Jordan Journal: Ann Oncol Date: 2020-02 Impact factor: 32.976
Authors: Norihiro Yamaguchi; Takeo Fujii; Shunsuke Aoi; Peter S Kozuch; Gabriel N Hortobagyi; Ronald H Blum Journal: Eur J Cancer Date: 2015-09-03 Impact factor: 9.162
Authors: Nidaa Mikail; Alexia Rossi; Susan Bengs; Ahmed Haider; Barbara E Stähli; Angela Portmann; Alessio Imperiale; Valerie Treyer; Alexander Meisel; Aju P Pazhenkottil; Michael Messerli; Vera Regitz-Zagrosek; Philipp A Kaufmann; Ronny R Buechel; Cathérine Gebhard Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-17 Impact factor: 10.057
Authors: Lars Lind; Jesus A Araujo; Aaron Barchowsky; Scott Belcher; Brian R Berridge; Nipavan Chiamvimonvat; Weihsueh A Chiu; Vincent J Cogliano; Sarah Elmore; Aimen K Farraj; Aldrin V Gomes; Cliona M McHale; Kathleen B Meyer-Tamaki; Nikki Gillum Posnack; Hugo M Vargas; Xi Yang; Lauren Zeise; Changcheng Zhou; Martyn T Smith Journal: Environ Health Perspect Date: 2021-09-24 Impact factor: 9.031